vomiting/비만증

FIELD OF THE INVENTION This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists

BACKGROUND OF THE INVENTION Gastrointestinal stimulation, or pacing, was advocated as a possible treatment for gastric motor dysfunction as early as 1963. Experimentation in the late 1960s and early 1970s, began to demonstrate the significance of gastrointestinal myoelectrical activity and its

TECHNICAL FIELD The present invention relates generally to a method of modulating substance P by compounds containing calcium sulfate, particularly syngenite, gorgeyite and gypsum, and more specifically, to the synthesis of such compounds as well as their use to treat a variety of conditions

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinone carboxamides and derivatives thereof of formula I, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinonecarboxamides and derivatives thereof of formula 1, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

FIELD OF THE INVENTION This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also

FIELD OF THE INVENTION The present invention relates to sulfonamide derivatives, to the process for preparing them and to their therapeutic use. BACKGROUND OF THE INVENTION Orexins A and B (or hypocretins 1 and 2) are hypothalamus neuropeptides of 33 and 28 amino acids, respectively, recently

FIELD OF THE INVENTION This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds that may be agonists or antagonists that are potentially useful in therapy, and to production of such polypeptides and

BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like

BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like

BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in